Paul Hastings, Nkarta CEO

Nkar­ta re­veals its first off-the-shelf NK cell da­ta, show­ing mul­ti­ple com­plete re­spons­es — shares soar

Near­ly two years af­ter pric­ing its IPO, Nkar­ta is fi­nal­ly re­port­ing its first clin­i­cal da­ta Mon­day.

The South San Fran­cis­co biotech re­vealed the first hu­man …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.